Franklin Genomic Adv ETF

Stanley Druckenmiller's Dukus Family Office Increases Stake in Natera Inc.

Robert Herdman Disposes of Adaptive Biotechnologies Corporation Common Stock

Jan Malcolm of Combined Therapeutics Reports Sale of Common Stock

CEO of United Therapeutics Disposes of Company's Common Stock

Natera Inc. and MEDSIR Initiate Clinical Trial for HR+/HER2- Breast Cancer

Guardant Health director sells 1,250 shares at $105 per share

Guardant Health Inc. collaborates with Trial Library to enhance cancer clinical trial accessibility

Nebula Research Increased Stake in Insmed Inc.

HighVista Strategies LLC Increases Holdings in BridgeBio Pharma

Aliram Pharmaceutical Repurchased $51.9 Million Convertible Notes

Guardant Health's CTO Darya Chudova Sells 22,935 Shares

Guardant Health Inc executive Kalia Kumud sold 2,000 shares

Guardant Health Director Disposes of Company Common Stock

Natera Announces Signatera MRD Test as Prognostic Biomarker for Breast Cancer Recurrence Risk

Insiders of United Therapeutics sold $3,833,374 worth of shares

Nilda Mesa Sold Shares of Combined Therapeutics

BridgeBio Launches Clinical Trial of BBO-10203 for Advanced Solid Tumors

Maricel Apuli Reports Sale of BridgeBio Pharma Inc. Common Stock

Cerity Partners LLC Increases Stake in Natera, Inc.

Insmed Director Sells $4.1M in Shares, Rothschild Upgrades to Buy

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

ADPT

Hershberg Robert Director of Adaptive Biotechnologies Corp [ADPT] filed a Form 4 on December 12, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/10/25TransactionSaleShares22,968Price$16.00Value$367,488Ending Holdings: 46,722 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Reuters

Adaptive Biotechnologies

Dir Hershberg Sells 22,968 ($367.5K) Of Adaptive Biotechnologies Corp [ADPT]

Director Robert Hershberg reported the disposal of common shares of Adaptive Biotechnologies Corporation. The full filing is available via EDGAR, the U.S. SEC's system.

Director Robert Hershberg Reports Disposal of Adaptive Biotechnologies Common Shares

UTHR

Malcolm Jan Director of United Therapeutics Corp [UTHR] filed a Form 4 on December 12, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/11/25TransactionPlanned Sale(1) Shares50Price$482.98Value$24,149Ending Holdings: 470 - Direct(1) Executed pursuant to a prearranged trading plan (10b5-1).For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

United Therap

Dir Malcolm Sells 50 ($24.1K) Of United Therapeutics Corp [UTHR]

Martine A. Rothblatt, Chairman of United Therapeutics Corp, sold 8,000 shares worth $3.9M, as disclosed in a Form 4 filed with the SEC. The transaction was executed under a prearranged trading plan (10b5-1). Ending holdings are 639,489 shares. The Washington Service offers insider trading analysis and data services.

Chmn Rothblatt Sells 8,000 ($3.9M) Of United Therapeutics Corp [UTHR]

Jan Malcolm, Director of United Therapeutics Corporation, reported the sale of common shares. The full filing is available via EDGAR, the U.S. SEC's system. This information is for informational purposes only and not financial advice.

United Therapeutics Director Jan Malcolm Reports Sale of Common Shares

Martine A. Rothblatt, CEO of United Therapeutics, reported the disposal of common shares of the company. The filing is available via EDGAR, the SEC's system. This AI-generated news is for informational purposes and not financial advice.

United Therapeutics CEO Martine Rothblatt Reports Disposal of Common Shares

NTRA

Natera Inc. and MEDSIR have launched the MiRaDoR phase II clinical trial for HR+/HER2- breast cancer, using Natera's Signatera Genome technology to evaluate treatment effectiveness. The trial aims to set a new standard in precision oncology by assessing treatment combinations' ability to reduce circulating-tumor DNA. Supported by F. Hoffman-La Roche Ltd., the trial is enrolling patients across multiple sites, with plans for expansion in Europe.

Natera

Natera and MEDSIR Launch MiRaDoR Trial in HR+/HER2- Breast Cancer

Guardant Health Director Medina Manuel Hidalgo sold 1,250 shares at $105 each, totaling $131,250. This sale reduced his position by 61.06%. The stock traded down 0.6% to $102.62. Analysts have given the stock a "Moderate Buy" rating with a target price of $80.86. Institutional investors have adjusted their positions in the company.

Market Beat

Guardant Health

Guardant Health (NASDAQ:GH) Director Sells $131,250.00 in Stock

Sheena Jonathan Director of Natera Inc [NTRA] filed a Form 4 on December 11, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/9/25TransactionExercise(1) Shares4,436Price$9.29Value$41,210Ending Holdings: 273,660 (227,096 - Direct, 46,564 - Indirect)(1) Exercised 2.2 years before expiration date.For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Dir Sheena Acquires 4,436 Of Natera Inc [NTRA]

BBIO

BridgeBio Oncology Therapeutics Inc. has granted stock options to a new employee under an inducement plan. The options allow the purchase of 53,060 shares at $12.88 each, vesting over four years. This announcement was made via GlobeNewswire on December 11, 2025.

Bridgebio Pharma

BridgeBio Oncology Therapeutics Grants Stock Options Under New Inducement Plan

Guardant Health Inc. has partnered with Trial Library to enhance access to cancer clinical trials in the U.S. by integrating genomic data with AI-powered patient matching. This collaboration aims to improve enrollment of diverse patient populations in precision oncology trials, offering new treatment opportunities and boosting participation in cancer research.

Guardant Health Partners with Trial Library to Expand Access to Cancer Clinical Trials

INSM

Nebula Research & Development LLC increased its stake in Insmed, Inc. by 985% in Q2, now holding 36,661 shares worth $3.69 million. Other investors also adjusted their positions. Insmed's stock performance showed a 52.4% revenue increase YoY, despite a Q3 EPS loss of $1.75. Analysts have given positive ratings, with price targets ranging from $135 to $215.

Insmed

Insmed, Inc. $INSM Shares Acquired by Nebula Research & Development LLC

HighVista Strategies LLC increased its stock position in BridgeBio Pharma, Inc. by 45.2% in Q2, owning 67,499 shares worth $2,915,000. Other institutional investors also modified holdings. Analysts have mixed ratings, with some raising target prices, indicating potential stock growth. BridgeBio Pharma's stock performance and insider transactions are under scrutiny.

HighVista Strategies LLC Increases Stock Position in BridgeBio Pharma, Inc. $BBIO

ALNY

Alnylam Pharmaceuticals Inc. has repurchased $34.4 million of its 2027 Convertible Senior Notes for $51.9 million, including interest. The repurchase price is linked to Alnylam's stock price over a measurement period starting December 11, 2025. $362.8 million of the notes remain outstanding, and capped call transactions related to these notes are still in effect.

Alnylam Pharma

Alnylam Repurchases $34.4 Million of 2027 Convertible Notes for $51.9 Million

Guardant Health Insider Sold Shares Worth $10,505,474, According to a Recent SEC Filing

marketscreener

Guardant Health Insider Sold Shares Worth $10,505,474, According to a Recent SEC Filing